Carcinogenesis and the central nervous system.

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Carcinogenesis, induced by 3-methylcholanthrene (3-MC), leads to tumor development and associated neuropathological changes.
• Paraneoplastic syndromes manifest as cerebral changes, including altered electroencephalogram (EEG) patterns, in tumor-bearing animals.
• Neurotransmitter imbalances, such as increased GABA and decreased monoamines, accompany carcinogenesis.

Purpose of the Study:

• To investigate the antineoplastic effects of central nervous system (CNS) drugs on tumor-bearing Wistar rats.
• To evaluate the impact of CNS drugs on tumor growth, survival time, remission rates, and chemotherapy toxicity.
• To explore the relationship between EEG changes, neurotransmitter metabolism, and tumor suppression.

Main Methods:

• Wistar rats were induced with the carcinogen 3-MC.
• Psychoactive drugs (piracetam, pyrithioxin, imipramine) were administered prophylactically and therapeutically.
• EEG monitoring, tumor assessment, survival analysis, and neurotransmitter level measurements were performed.

Main Results:

• CNS drugs exhibited a significant antineoplastic effect, increasing survival and remission.
• Combination therapy (CNS drugs with chemotherapy or surgery) yielded high remission rates and reduced toxicity.
• EEG abnormalities associated with tumors normalized after treatment with CNS drugs and surgical intervention.
• CNS drug treatment reversed carcinogenic-induced neurotransmitter imbalances.

Conclusions:

• Psychoactive and CNS drugs possess anticancer properties, offering therapeutic potential.
• Combined treatment strategies involving CNS drugs, chemotherapy, and surgery can enhance tumor suppression and cure rates.
• Carcinogenesis disrupts cyclic nucleotide and neurotransmitter metabolism, which CNS drugs can help rebalance for tumor suppression.